바로가기메뉴

본문 바로가기 주메뉴 바로가기

Tuberculosis & Respiratory Diseases

Article Contents

Prev Next
e-Submission

Vol.57 No.4
Citation Share

Concurrent Chemoradiation with Weekly Paclitaxel in Locally Advanced Non-small Cell Lung Cancer

Tuberculosis & Respiratory Diseases / Tuberculosis & Respiratory Diseases,
2004, v.57 no.4, pp.351-357







& (2004). Concurrent Chemoradiation with Weekly Paclitaxel in Locally Advanced Non-small Cell Lung Cancer. Tuberculosis & Respiratory Diseases, 57(4), 351-357.
  • Downloaded
  • Viewed
PDF Download

Abstract

Background : Paclitaxel is highly beneficial anticancer drug for the treatment of non-small cell lung cancer and has shown remarkable radiosensitizing effect in vitro. We evaluated whether concurrent chemoradiation therapy with weekly paclitaxel (60 mg/m2) could be tolerated and effective in the treatment of locally advanced non-small cell lung cancer (NSCLC). Methods : Twenty-two stage III (IIIA:6, IIIB:16) NSCLC patients were treated with weekly administration of paclitaxel (60 mg/m2) on days 1, 8, 15, 22, 29, and 36 in addition to concurrent radiation therapy of 54 Gy. After the initial phase of concurrent chemoradiation, patients received additional two cycles of consolidation chemotherapy with paclitaxel (175mg/m2)/cisplatin (75 mg/m2) or paclitaxel (175 mg/m2)/carboplatin (6AUC) every 3 weeks. Results : Overall response rate was 81.8% (18/22) with 9.1% (2/22) of complete response and 72.7% (16/22) of partial response rate. Two patients (9.1%) died of chemoradiation-induced pneumonitis after completion of therapy. In total, grade 3 toxicities included pneumonitis (22.7%), esophagitis (22.7%), neuropathy (13.6%), and neutropenia (13.6%). The median survival time was 15 months and 2-year overall survival were 31.8%. Conclusion : Concurrent chemoradiation therapy with weekly paclitaxel in locally advanced NSCLC showed good local response, but survival rate was not completely satisfactory due to potentially fatal chemoradiation-induced pneumonitis.(Tuberc Respir Dis 2004; 57:351-357)

keywords
NSCLC, Concurrent chemoradiation, Weekly paclitaxel.국소진행성 비소세포폐암에서 Paclitaxel 매주투여 및 방사선치료 동시요법단국대학교 의과대학 내과학교실배강우, 송탁호, 양주연, 김윤섭, 박재석, 지영구, 이계영*Concurrent Chemoradiation with Weekly Paclitaxel in LocallyAdvanced Non-small Cell Lung CancerKang Woo B, NSCLC, Concurrent chemoradiation, Weekly paclitaxel.국소진행성 비소세포폐암에서 Paclitaxel 매주투여 및 방사선치료 동시요법단국대학교 의과대학 내과학교실배강우, 송탁호, 양주연, 김윤섭, 박재석, 지영구, 이계영*Concurrent Chemoradiation with Weekly Paclitaxel in LocallyAdvanced Non-small Cell Lung CancerKang Woo B

Reference

1.

(1981) Radiotherapy in the management of locally advanced lung cancer of all cell types:final report of randomized trial,

2.

(1991) Five-year survival after hyperfractionated radiation therapy for non-small-cell carcinoma of the lung(NSCCL)results of RTOG protocol 81-08,

3.

(1990) A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer,

4.

(1995) Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer.,

5.

(1999) Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin,vindesine,and cisplatin in unresectable stage III non-small-cell lung cancer,

6.

(2000) Phase III comparison of sequential vs. concurrent chemoradiation for patients with unrescted stage III non-small cell lung cancer (NSCLC) initial report of Radiation Therapy Oncology Group (RTOG) 9410,

7.

(2001) Paclitaxel-based combination chemotherapy in advanced non-small cell lung cancer,

8.

(1995) Role of reoxygenation in induction of enhancement of tumor radioresponse by paclitaxel,

9.

(1994) Enhancement of tumor radioresponse of a murine mammary carcinoma by paclitaxel,

10.

(2001) Radiosensitization with chemotherapeutic agents,

11.

(1997) Paclitaxel as a radiosensitizer:a proposed schedule of administration based on in vitro data and pharmacokinetic calculations,

12.

(1981) Reporting results of cancer treatment,

13.

(2000) Locally advanced, unresectable non- small cell lung cancer: new treatment strategies,

14.

(2000) Combined modality therapy for unresectable stage III non-small cell lung cancer: new chemotherapy combinations,

15.

(2001) Combined modality treatment with chemotherapy and radiation in locally advanced non-small cell lung cancer,

16.

(1996) Improved survival in stage III non- small-cell lung cancer:seven-year follow-up of cancer and leukemia group B [CALGB] 8433 trial,

17.

(2000) Final results of phase III trial in regionally advanced unresectable non- small cell lung cancer:Radiation Therapy Oncology Group,Eastern Cooperative Oncology Group,and Southwest Oncology Group,

18.

(1992) Significant effect of adjuvant chemotherapy on survival in locally advanced non-small-cell lung carcinoma,

19.

(2001) Optimizing chemoradiation therapy approaches to unresectable stage III non-small cell lung cnacer,

20.

(2001) A quality-adjusted time without symptoms or toxicity (QTWIST). Analysis of Radiation Therapy Oncology Group [RTOG] 9410,

21.

(2001) Combined chemotherapy and radiation in locally advanced non-small cell lung cancer,

22.

(2002) Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: cancer and leukemia group B study 9431,

23.

(1994) Phase I trial of outpatient weekly paclitaxel and concurrent radiation therapy for advanced non-small cell lung cancer,

24.

(1995) Paclitaxel(taxol),

25.

(1999) Pacltaxel and concurrent radiotherapy in locally advanced non-small cell lung cancer:the Canadian experience,

Tuberculosis & Respiratory Diseases

e-Submission OA Policy